ABT-737, Synergistically Enhances Daunorubicin-Mediated Apoptosis in Acute Myeloid Leukemia Cell Lines

ABT-737, Synergistically Enhances Daunorubicin-Mediated Apoptosis in Acute Myeloid Leukemia Cell Lines

Purpose: Intensive chemotherapy with daunorubicin (DNR) is associated with serious side effects in acute myeloid leukemia (AML) patients. In this study the effect of small-molecule BH3-mimetic, ABT-737, on the sensitivity of HL60 and U937 AML cell lines was investigated. Methods: The cytotoxic effe...

Full description

Bibliographic Details
Main Authors:	Hassan Dariushnejad, Nosratallah Zarghami, Mohammad Rahmati, Samaneh Ghasemali, Zohreh Sadeghi, Zahra Davoodi, Hossein Jafari Tekab, Masoud Gandomkar Ghalhar
Format:	Article
Language:	English
Published:	Tabriz University of Medical Sciences 2014-03-01
Series:	Advanced Pharmaceutical Bulletin
Subjects:	Acute myeloid leukemia Daunorubicin ABT-737 Combination Apoptosis
Online Access:	http://journals.tbzmed.ac.ir/APB/Manuscript/APB-4-185.pdf

Similar Items

ABT-737 synergizes with Bortezomib to kill melanoma cells
by: Steven N. Reuland, et al.
Published: (2012-02-01)

The Application of Arsenic Trioxide in Ameliorating ABT-737 Target Therapy on Uterine Cervical Cancer Cells through Unique Pathways in Cell Death
by: I-Lun Hsin, et al.
Published: (2019-12-01)

Synergistic co-delivery of diacid metabolite of norcantharidin and ABT-737 based on folate-modified lipid bilayer-coated mesoporous silica nanoparticle against hepatic carcinoma
by: Minchen Liu, et al.
Published: (2020-08-01)

BCL2L10 Is Overexpressed in Melanoma Downstream of STAT3 and Promotes Cisplatin and ABT-737 Resistance
by: María Josefina Quezada, et al.
Published: (2021-12-01)

Melatonin Can Modulate the Effect of Navitoclax (ABT-737) in HL-60 Cells
by: Alexey Lomovsky, et al.
Published: (2020-11-01)

ABT-737 reverses the acquired radioresistance of breast cancer cells by targeting Bcl-2 and Bcl-xL
by: Li Ji-Yu, et al.
Published: (2012-12-01)

The BH3-mimetic ABT-737 effectively kills acute myeloid leukemia initiating cells
by: Denis V. Baev, et al.
Published: (2014-01-01)

Cooperation of IRAK1/4 inhibitor and ABT-737 in nanoparticles for synergistic therapy of T cell acute lymphoblastic leukemia
by: Wu X, et al.
Published: (2017-10-01)

Glycycoumarin Sensitizes Liver Cancer Cells to ABT-737 by Targeting De Novo Lipogenesis and TOPK-Survivin Axis
by: Enxiang Zhang, et al.
Published: (2018-03-01)

An Anti-PSMA Immunotoxin Reduces Mcl-1 and Bcl2A1 and Specifically Induces in Combination with the BAD-Like BH3 Mimetic ABT-737 Apoptosis in Prostate Cancer Cells
by: Anie P. Masilamani, et al.
Published: (2020-06-01)

ABT-737, a small molecule Bcl-2/Bcl-xL antagonist, increases antimitotic-mediated apoptosis in human prostate cancer cells
by: Ricardo Parrondo, et al.
Published: (2013-09-01)

Mécanismes moléculaires de l'acquisition d'une sensibilité à l'apoptose induite par l'ABT-737 et d'une résistance à l'anoïkis de cellules coliques métastatiques
by: Maamer - Azzabi, Aida
Published: (2013)

Inhibition des protéines anti-apoptotiques de la famille Bcl-2 par l'ABT-737 : intérêt pour le traitement des cancers des voies aérodigestives supérieures
by: Gilormini, Marion
Published: (2015)

Carvedilol Attenuates Inflammatory-Mediated Cardiotoxicity in Daunorubicin-Induced Rats
by: Punniyakoti T. Veeravedu, et al.
Published: (2011-03-01)

Potential effects of pomegranate on lipid peroxidation and pro-inflammatory changes in daunorubicin-induced cardiotoxicity in rats
by: Hayder M Al-Kuraishy, et al.
Published: (2016-01-01)

Experimental inhibition of proliferative vitreoretinopathy in retinal detachment using daunorubicin
by: Kumar Atul, et al.
Published: (1994-01-01)

Intrinsic and extrinsic apoptosis responses in leukaemia cells following daunorubicin treatment
by: Hussain Mubarak Al-Aamri, et al.
Published: (2021-04-01)

Nuclear Lipid Microdomains Regulate Daunorubicin Resistance in Hepatoma Cells
by: Michela Codini, et al.
Published: (2018-11-01)

A Pilot Study of Matrix Metalloproteinases on the Model of Daunorubicin-induced Cardiomyopathy in Rabbits
by: Anna Potáčová, et al.
Published: (2007-01-01)

Effects of Tg737 on cell cycle progression and cell invasion in liver cancer
by: Wei Zhang, et al.
Published: (2018-03-01)

Novel formulation of cytarabine and daunorubicin: A new hope in AML treatment
by: Lalit S Raut
Published: (2015-01-01)

Liposomal daunorubicin and dexamethasone as a treatment for multiple myeloma: the DD Protocol
by: Frederico Luiz Dulley, et al.

Quercetin as a Potential Modulator of P-Glycoprotein Expression and Function in Cells of Human Pancreatic Carcinoma Line Resistant to Daunorubicin
by: Piotr Dziegiel, et al.
Published: (2010-02-01)

Fluorescence spectra of cardiac myosin and in vivo experiment: studies on daunorubicin-induced cardiotoxicity
by: Yang Liu, et al.
Published: (2015-12-01)

Anti-CD123 antibody-modified niosomes for targeted delivery of daunorubicin against acute myeloid leukemia
by: Fu-rong Liu, et al.
Published: (2017-01-01)

Mécanismes moléculaires de l'acquisition d'une sensibilité à l'apoptose induite par l'ABT-737 et d'une résistance à l'anoïkis de cellules coliques métastatiques.
by: Maamer - Azzabi, Aida
Published: (2013)

Tg737 signaling is required for hypoxia-enhanced invasion and migration of hepatoma cells
by: You Nan, et al.
Published: (2012-09-01)

Crosstalk Between Apoptosis and Autophagy : BH3 Mimetics Activate Multiple Pro-Autophagic Pathways
by: Malik, Shoaib Ahmad
Published: (2012)

Daunorubicin induced Stevens‐Johnson syndrome: A case report
by: Preeti Shakya, et al.
Published: (2021-07-01)

THE ROLE OF BCL-2 FAMILY IN CLINICAL RESPONSE OF CHRONIC LYMPHOCYTIC LEUKEMIA
by: ALHARBI, SAYER RASHED
Published: (2012)

Different influence of Arac combined with idarubicin and with daunorubicin on malignant molecule expression of acute myelocytic leukemia
by: Abudourexiti Nuerbiya, et al.
Published: (2018-05-01)

Applications of daunorubicin-loaded PLGA-PLL-PEG-Tf nanoparticles in hematologic malignancies: an in vitro and in vivo evaluation
by: Bao W, et al.
Published: (2019-04-01)

Olaparib Synergizes the Anticancer Activity of Daunorubicin via Interaction with AKR1C3
by: Tássia S. Tavares, et al.
Published: (2020-10-01)

Reformulating acute myeloid leukemia: liposomal cytarabine and daunorubicin (CPX-351) as an emerging therapy for secondary AML
by: Chen EC, et al.
Published: (2018-06-01)

Troponin-I and left ventricular function in pediatric high-risk acute lymphoblastic leukemia after daunorubicin treatment
by: Rinche Annur, et al.
Published: (2021-03-01)

MiR-15a-5p Confers Chemoresistance in Acute Myeloid Leukemia by Inhibiting Autophagy Induced by Daunorubicin
by: Emeline Bollaert, et al.
Published: (2021-05-01)

Synergistic Effects of TW-37 and ABT-263 on Renal Cell Carcinoma Cells
by: Yu R, et al.
Published: (2021-02-01)

Antioxidant activity of selected phenols estimated by ABTS and FRAP methods
by: Izabela Biskup, et al.
Published: (2013-09-01)

Effect of daunorubicin drug with and without cimetidine on the nucleated cells of bone marrow of balb/c mouse
by: ali asghar Kiani, et al.
Published: (2004-01-01)

Daunorubicin reduces MBNL1 sequestration caused by CUG-repeat expansion and rescues cardiac dysfunctions in a Drosophila model of myotonic dystrophy
by: Mouli Chakraborty, et al.
Published: (2018-04-01)